Hospital-based use of thromboprophylaxis in patients with COVID-19
- PMID: 32330428
- PMCID: PMC7173816
- DOI: 10.1016/S0140-6736(20)30926-0
Hospital-based use of thromboprophylaxis in patients with COVID-19
Comment on
-
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13. J Thromb Haemost. 2020. PMID: 32073213 Free PMC article.
References
-
- Obi AT, Tignanelli CJ, Jacobs BN. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. J Vasc Surg Venous Lymphat Disord. 2019;7:317–324. - PubMed
-
- Cohoon KP, De Sanctis Y, Haskell L, McBane RD, Spiro TE. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. J Thromb Haemost. 2018;16:1278–1287. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources